ISIA Board of Directors and Officers

  • VP of Operations and Communication

    Central Biomedia Inc.

    Nicole Green has been involved in the animal serum industry for over 20 years and is currently Vice President of Operations and Communication at Central Biomedia, Inc. She has served in many different roles including quality, production, and management. During her tenure she has been responsible for regulatory affairs, quality, business development, and overall company culture. Nicole has been actively involved in the ISIA as leader of the Traceability Team and is now board chair.

    Nicole believes in providing safe materials to end users who are producing and researching life-saving products for humans and animals.

    Nicole holds a BA in Biology from MidAmerica Nazarene University. She enjoys reading, listening to podcasts, and learning something new every day. She resides in Kansas City, Missouri with her husband and two children.

Mark Koza

  • Business Director for Serum

    Corning Life Sciences

    Mark Koza serves as Business Director for Media & Serum at Corning Life Sciences, where he has spent his two-decade career. He is responsible for strategy and execution of Corning's global serum portfolio, which includes all stages in the supply chain from supply to customer.

    Over the years at Corning Life Sciences, Mark has held various roles in commercial and business operations, most recently as Global Business Manager for Serum. He is also a member of the ISIA Traceability team and serves as the ISIA board chair-elect.

    Mark received his bachelor’s degree in microbiology from The University of Maine. Outside of work, Mark lives with his wife and two children in the beautiful Seacoast region of New Hampshire.

Jim Crean

  • General Manager/Senior Director, Sera Business Segment

    Thermo Fisher Scientific

    Jim is currently GM/Senior Director, leading the Global Sera Business Segment at Thermo Fisher Scientific. He joined Invitrogen, Gibco Sera division in 2007 as Director, Sera Global Supply Chain Operations, prior to the acquisition by Thermo Fisher Scientific.

    Since 2008, Jim has served on the board of directors for the International Serum Industry Association (ISIA) and held numerous positions within the association, including Vice Chair, Chairman of the Board, and participant on various sub-committees.

    Prior to joining Thermo Fisher Scientific, Jim’s experience has been predominantly in supply chain leadership positions with Nestle Purina & other consumer goods companies. He obtained his Bachelor of Science, Business Management with concentrations in Accounting and Finance from the University of New York at Buffalo.

  • Director of Product Management

    Cytiva

    Jared Deppe is the Director of Product Management - Sera, Research, and OEM Products within Cytiva’s cell culture business (HyClone). He manages commercial and product strategies for HyClone serum and research portfolios with Cytiva. 

    His 20-year career includes various roles in pricing, finance, and product management.  For the last 10 years, Jared has been a leader within Cytiva’s serum portfolio and the serum industry. Jared has also served in multiple functions within the ISIA including as CFO and as an active member of the traceability committee. 

    Jared holds a Bachelor’s degree from Utah State University in Finance and Economics and a Master’s degree in Business Administration (MBA) from Weber State University.   

    He resides in Northern Utah with his wife and three daughters. 

  • International Sales Manager

    River City Biologicals, River City Brazil, and Animal Technologies, Inc.

    Ph.D. in Business Administration, Guilherme Esteves is a Board Member of the International Serum Industry Association (ISIA) and holds positions as International Sales Manager at River City Biologicals, River City Brazil, and Animal Technologies, Inc.

    With 15+ years of experience in planning and management of commercial, administrative, and financial areas of small and medium-sized companies, Esteves has been working for 11+ years as an entrepreneur, focusing on new business development.

Jenny Murray

  • Managing Director, ISIA, Past Board Chair

    Life Science Group Ltd.

    Jenny has over 30 years’ experience in the cell culture industry, both in the UK and worldwide. Jenny is the past owner of Seralab Ltd. and the current owner of Life Science Group Ltd. (LSG). LSG is an independent manufacturing company based in the UK offering contract manufacturing of various human and animal sera, media and buffers for research, cell therapy and other disciplines. LSG also offers the contract manufacture of antibodies, monoclonal and polyclonal, together with a large range of associated services.

    Jenny is very active in support of European Regulatory Affairs, Traceability and Standardization within the Association. She recently served 3 years as the Chair of the ISIA Board of Directors.

Vlad Tutitun

  • Head of Operations

    Moregate Biotech

    Originally from Ukraine, Vlad graduated from the National University of Life and Environmental Sciences of Ukraine (formerly National Agricultural University) with a degree in veterinary medicine with honors.

    After moving to Australia in 2012 he worked as a beef farm manager prior to joining Moregate Biotech in 2017 and has worked though all levels of the business, from Production Manager to General Manager.

    He enjoys the daily challenges, loves to contribute and support the company’s growth, and is fascinated by the vastness of animal serum applications on a global scale. Inspired by James Dunster and Elizabeth Meixner, Vlad’s role has grown to manage the operations of Moregate under new owners after the company was acquired by ANZCO foods in 2022.

    Vlad lives with his wife and two children in Brisbane, Australia.

Gareth Williams

  • Sales and Marketing Director

    TCS Biosciences

    Gareth has worked for TCS Biosciences Ltd (TCS) for over 20 years and has held the position of Sales and Marketing Director since 2006. TCS is a manufacturer and distributor of a wide range of animal and human derived blood and serum products.

    We produce Donor Horse Serum from our herds based on our farm in the UK. It is essential that we maintain high quality standards in all aspects of serum production from animal husbandry, through collection to processing and packaging to ensure consistent top-quality products. We recognize that traceability is of prime importance to our customers, and we are renowned for the quality of our documentation trail and our rapid response to specialist customer requirements.

    As well as our own manufactured products, we work with carefully selected strategic partners from around the globe importing Bovine Serum products, including Fetal Bovine Serum, for supply to our customers in the UK and Europe.

    TCS has been a member of the ISIA for many years and take active roles in some of the sub committees. In 2017 we confirmed our commitment to quality and ethics by becoming ISIA Traceability Certified. This certification covers the manufacture and supply of our own Donor Horse Serum, and the import, handling and logistical pathway of Bovine Serum products sourced from our ISIA Traceability Certified partners.

Andres Monroy

  • Founder & CEO

    Ambioxera Pty Ltd

    Mr. Monroy a wealth of experience and expertise in quality management, strategic leadership, and operational excellence to the table. With a dynamic background spanning various sectors including biotechnology, healthcare, and manufacturing, he has consistently demonstrated a commitment to driving organizational success through innovation, collaboration, and thorough attention to detail.

    As the Chief Executive Officer and founder of Ambioxera Pty Ltd, Mr. Monroy exemplifies visionary leadership, spearheading the company's strategic direction while fostering a culture of continuous improvement and customer-centricity. His track record of effectively navigating complex regulatory landscapes and ensuring adherence to stringent quality standards underscores his dedication to excellence in every aspect of business operations. He is playing a pivotal role in shaping the company's trajectory by developing and implementing strategic initiatives that drive growth and sustainability.

    With a Master's degree in Applied Science with an emphasis in Biotechnology and an MBA with a focus on General Management and more than 10 years of experience in the serum industry, Mr. Monroy possesses a unique blend of technical expertise and business acumen. His bilingual proficiency in Spanish and English further enhances his ability to connect with diverse stakeholders and navigate global business landscapes with ease.

  • ISIA CEO

    Ding Ming, PhD, is Chief Executive Officer at International Serum Industry Association (ISIA) leading overall ISIA strategies, organizations, and operations worldwide. Dr. Ming brings extensive leadership experience and scientific expertise to ISIA, with a strong background in life sciences and a deep commitment to quality, traceability, and ethical standards across the global serum industry. His strategic vision and collaborative approach will be instrumental in advancing ISIA’s mission and strengthening industry practices worldwide.

    Dr Ming is a seasoned pharmaceutical executive with more than 25 years of pharma operational leadership experience. He was the SVP & GM for Thermo Fisher Scientific Clinical Research China Operations leading an organization of 1600+ healthcare professionals in contracting clinical trials and laboratory services to deliver a business revenue of 250+ million US dollars annually. Before his Thermo Fisher career, Dr Ming was the VP and WW R&D Head for Emerging BioSolutions leading an organization of 400+ professionals and delivering a diversified biologics pipeline to support a global business of 3.5 billion US dollars. He was also the Global VP of Research and Innovation for United States Pharmacopeial Convention (USP) working closely with US FDA to create and optimize scientific substantiation and standardization for new and existing FDA regulations.  Dr Ming was the Global Wellness Category R&D Head and Director of Medical Affairs at GSK supporting a business with an annual sale of 4 billion US dollars. He was also a founding member of GSK China R&D to establish a scientific and medical organization for the GSK APAC Region. Prior to GSK, he worked at a variety of pharmaceutical companies including Boehringer Ingelheim, Schering Plough, Pfizer, and Novartis, participated, and led many global and regional scientific, medical, and clinical development programs.

    Dr. Ming received his PhD in Animal Health & Biomedical Sciences from University of Wisconsin-Madison, MS from Chinese Academy of Sciences, and BS from Inner Mongolia University in China. He was a Dana Farber Research Fellow in Immunology at Harvard Medical School, and a Howard Hugh Medical Institution(HHMI) Postdoctoral Research Fellow in Pharmacology at the Mount Sinai School of Medicine of New York University. Before joining industry, Dr Ming taught molecular biology courses at Fudan University, Shanghai, China.

    Dr Ding Ming is the author of many pioneering research publications on a list of peer reviewed scientific journals including NATURE and PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS). He is the inventor for 9 US and European patents. Dr Ming is recognized as an active global thought leader, and served leadership roles in industrial alliance/professional organizations including ILSI-NA, CHPA, DIA, and ChinaTrials. He was selected as a member of 100 Honorable Overseas Chinese Scientist Group by China government in 1999.

Natalie Robinson

  • Natalie Robinson is the ISIA CFO. She joined in January 2024. She works as the Head of Planning & Finance for a large national non profit.

Kathryn Pagani-Lee

  • Kathryn Pagani-Lee is the Director of Administration and Board Secretary at the International Serum Industry Association (ISIA). Since joining ISIA in 2021, she has played a pivotal role in managing administrative operations, coordinating board activities, overseeing the successful execution of the ISIA Annual Meeting, and fostering strong member relations.

    With a deep commitment to ISIA’s mission, Kathryn ensures the seamless operation of the association while supporting initiatives that promote traceability, regulatory compliance, and ethical standards within the global serum industry. Her expertise in organizational management and stakeholder engagement has been instrumental in strengthening ISIA’s industry presence and enhancing collaboration among its members. 

    Based in Ontario, California, Kathryn continues to drive ISIA’s efforts to uphold the highest standards in the serum and biological products sector, ensuring its members receive exceptional support and guidance.